Results 51 to 60 of about 12,187 (203)

Risk factors for administration of additional neuromuscular block reversal in adults undergoing general anaesthesia: a single centre retrospective case-control study

BMC Anesthesiology
Background Residual neuromuscular block continues to be a modifiable risk factor for major postoperative pulmonary complications in adults. Methods We performed a large retrospective case-control study at a single center to evaluate both the prevalence ...
Susan R. Vishneski, Amit K. Saha, Lan C. Tran, Rohesh J. Fernando, Suneeta K. Acharya, Lisa K. Lee, Leah B. Templeton, Amber K. Brooks, L. Daniela Smith, T. Wesley Templeton   +9 more
doaj   +1 more source

Required dose of sugammadex or neostigmine for reversal of vecuronium‐induced shallow residual neuromuscular block at a train‐of‐four ratio of 0.3

Clinical and Translational Science, 2022
Residual shallow neuromuscular block (NMB) is potentially harmful and contributes to critical respiratory events. Evidence for the optimal dose of sugammadex required to reverse vecuronium‐induced shallow NMB is scarce. The aims of the present study were
Jing He, Huan He, Xing Li, Mei Sun, Zhihao Lai, Bo Xu   +5 more
doaj   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Effects of Sugammadex and Neostigmine on Renal Biomarkers

, 2016
Background: Neostigmine, the currently commonly used agent for reversal of neuromuscular blockade. Sugammadex is a novel and unique compound designed as an antagonist of steroidal neuromuscular blockers.
Isik, Yasemin and Palabiyik, Onur and Cegin, Bilal Muhammed and Goktas, Ugur and Kati, Ismail
core   +2 more sources

AEG‐AESPANC‐OPGE‐SIED‐SPG Ibero‐Latin American Guidelines on Acute Pancreatitis (iLATAM‐AP)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Introduction Acute pancreatitis (AP) is a major cause of gastrointestinal hospitalizations worldwide. Although typically self‐limiting, up to one‐third of cases develop complications associated with increased morbidity and mortality. Despite recent advances that have improved outcomes, clinical heterogeneity necessitates updated, evidence ...
Karina Cárdenas‐Jaén, Lucía Guilabert, Emma Martínez‐Moneo, Carla Mancilla, Miguel Bispo, Pedro Moutinho‐Ribeiro, Rodrigo Mansilla, Andreia Rei, Ana García García de Paredes, Antonio López‐Serrano, Bruno Rosa, Claudia Sánchez‐Marín, Daniel de la Iglesia, Edson Guzmán‐Calderon, Eduardo Rodrigues‐Pinto, Eva Marín‐Serrano, Fabio Ausania, Fauze Maluf‐Filho, Guido Villagómez, Humberto Cristino, Isabel Pascual‐Moreno, José A. Gonzalez, José M. Ramia, João Lopes‐Delgado, Lucas Granero, Mario Peláez‐Luna, María Francisco, Natalia Corzo‐Zamora, Ricardo Rio‐Tinto, Rómulo D. Vargas, Sandra Basso, Susana Lopes, Susana Marques, William Manzanares, Zoltán Berger, Irene Carrillo, José Joaquín Mira‐Solves, Alberto Espino, Adriana Cowdin, Alejandro Piscoya, Alexandra Fernandes, Noelia Rodríguez‐Ferreiro, Neftalí Jara Pérez‐López, Beatriz Valero, Enrique de‐Madaria   +44 more
wiley   +1 more source

Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center

ClinicoEconomics and Outcomes Research, 2016
Michele Carron, Fabio Baratto, Francesco Zarantonello, Carlo Ori Department of Medicine, Anesthesiology and Intensive Care, University of Padova, Padova, Italy Objective: The aim of the study is to evaluate the clinical and economic impact of introducing
Carron M, Baratto F, Zarantonello F, Ori C   +3 more
doaj  

Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution

Case Reports in Anesthesiology, 2017
Neostigmine has been traditionally used as the agent of choice to reverse Neuromuscular Blockade (NMB) after muscle paralysis during general anesthesia. However, the use of neostigmine has not been without untoward events. Sugammadex is a novel drug that
Michael S. Green, Archana Gundigi Venkatesh, Ranjani Venkataramani   +2 more
doaj   +1 more source

Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: a double blind prospective randomized controlled trial

BMC Anesthesiology, 2019
Background The use of neostigmine after neuromuscular blockade (NMB) has been associated with postoperative respiratory complications. In previous studies, we found lower diaphragmatic activity after neostigmine reversal of NMB, compared to sugammadex ...
Tom Schepens, Koen Janssens, Sabine Maes, Davina Wildemeersch, Jurryt Vellinga, Philippe G. Jorens, Vera Saldien   +6 more
doaj   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock, Timothy C. Hardcastle, Christine Gaarder, Amit Gupta, Adam Gyedu, Manjul Joshipura, Elmin Steyn, on behalf of the Essential Trauma Care revision author group, Valencia Adjei, Roger Alcock, Vanda Amado, Michael Boampong, Sanjeev Booi, Petra Brysiewicz, Corazon Cabanilla‐Manuntag, Cristiane de Alencar Domingues, Ghada Elhadari, Ranjith Nanda Ellawala, Sarnai Erdene, Ama Akoma Essuman, Jorge Esteban Foianini, Filippo Gatti, Armando Garcia Guererra, Greg Hynes, Adil Haider, Sandy Ingless, Balavenkata Jagannathan, Helen Jowett, Knut Magne Kolstadbråten, Sonja Krofak, Aireen Patricia Madrid, Tina Tomić Mahečić, Claude Martin, Daniel Ntogwrachu, Bisola Onajin‐Obembe, Nhobojit Roy, Andres Rubiano, Niisoja Mensah Torto, Ben Wachira, Meg Walmsley, Torben Wisborg, Elma Wong   +41 more
wiley   +1 more source

Economic evidence for licensed ready‐to‐administer intravenous products compared with standard vials and ampoules: a systematic review

Anaesthesia, Volume 81, Issue 6, Page 867-874, June 2026.
Summary Introduction Injectable medicines represent a significant proportion of the annual medicines expenditure of the NHS in England, totalling £7 billion ($9.4 billion, €8.0 billion) in 2023. This represents approximately 70% of hospital medicines spending and includes essential treatments delivered at the point of care, such as chemotherapy ...
Suzanne Al‐Rawi, Matthew Greening, Sue Ladds   +2 more
wiley   +1 more source